Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption.

Rhythm expands obesity portfolio with Phase II weight loss drug for $100m

Share this article Rhythm will assume sponsorship of two Phase II trials investigating LG Chem’s LB54640, as part of the agreement. Image Credit: Alex Verrone

January 5, 2024

Aledade Raises $260M to Expand Services for Network of Primary Care Practices

What You Should Know: Aledade, a Bethesda, MD-based network of independent primary care practices raises $260M in a Series F funding round led by new

June 21, 2023

Does COVID-19 Persist?

Does COVID-19 persist in the body? With 17 million adults reporting long COVID symptoms like brain fog and fatigue, the idea of viral persistence has

May 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.